3Daughters Secures $4.7 Million in Oversubscribed Seed Round
2024年7月11日 - 9:00PM
3Daughters, Inc., a clinical development company fueling
evolutionary healthcare for women, announced successful completion
of an oversubscribed Seed financing round of $4.7M. This round
included participation from existing investors Thairm Bio, Argosy
Foundation, Wexford Science and Technology, LLC, UMass Amherst, and
new undisclosed investors. Previously, the company had announced
the close of the first tranche of this financing round, exceeding
$2 million.
The additional investor participation underscores the growing
significance and need for innovation in Women’s Health and
particularly for contraception, a growing $8 billion dollar market
in the U.S. Women use contraceptives on average for 30 years and
improved options are needed.
Mary Beth Cicero, CEO of 3Daughters, commented, “We are thrilled
by the overwhelming response from both our existing and new
investors who share our determination and dedication to improving
therapies for women, starting with our advanced IUD and integrated
system for insertion and retrieval. Notably, this oversubscribed
round supports our preclinical development through an IND filing in
early 2025, a major milestone in our development timeline.”
Research indicates that over 275 million women worldwide use
intrauterine devices (IUDs), with copper IUDs being the most
popular choice for non-hormonal, long acting, and reversible
contraception. 3Daughters’ lead asset (3D-001) is a frameless,
non-hormonal, magnetic IUD that self-assembles when placed in the
uterus and conforms to a woman’s body. 3D-001 is paired with a
patented inserter and retriever designed as an integrated system to
eliminate the three major pain points during the IUD insertion
process. A recent Wall Street Journal article highlighted the
well-known insertion pain that scares many women away from getting
one of the most effective forms of birth control.
3Daughters has launched a Series A financing round of $15M to
fund 3D-001’s first-in-human Phase 1 study expected to start
following IND approval in 2025.
About 3Daughters™3Daughters is a clinical
development company focused on evolutionary healthcare for women
where cutting-edge research and innovation is desperately needed.
The Company’s technology platform is based on physics and geometry
to deliver targeted therapy to the uterus. The first product,
(3D-001), is a frameless, magnetic, non-hormonal intrauterine
device (IUD) for long-acting contraception that conforms to a
woman’s body. Combined with our unique, patented Slider™ system
(for insertion and retrieval), this integrated system is expected
to eliminate the most painful steps in the insertion process as
well as the nuisance factor of strings (needed for removal).
3Daughters’ vision is to solve health issues for women,
particularly significant, and neglected, problems. 3Daughters plans
to radically disrupt the IUD market by addressing the major
adoption barrier — insertion pain. This pain is associated with all
current rigid, plastic T-shape framed IUDs on the market and
prevents women from selecting one of the most effective forms of
birth control. Visit 3daughtershealth.com for more
information.
ContactLouis ScottiSenior Vice President,
Business Operations & Corporate
Developmentlscotti@3daughtershealth.com